Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Hepatitis C
Interventions: XTL 6865; Drug
Lead sponsor: XTL Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Indianapolis, Indiana • New York, New York • Chapel Hill, North Carolina + 1 more

Conditions: Gentle Colonoscopy
Interventions: SC20 Colonoscope; Device
Lead sponsor: Invendo Medical GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: New York, New York

Conditions: Cervical Spondylotic Myelopathy
Interventions: riluzole, Placebo medication; Drug
Lead sponsor: AOSpine North America Research Network; Network
Eligibility: 18 Years to 80 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 15
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 11 more

Conditions: Hepatitis, Chronic Active
Interventions: CPG10101, Control; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 14
States / cities: Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more

Conditions: COVID-19 Infection
Interventions: Brequinar, Placebo; Drug
Lead sponsor: Clear Creek Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Homewood, Alabama • Long Beach, California • Doral, Florida + 11 more

Conditions: Heparin-induced Thrombocytopenia
Interventions: Warfarin, NOAC; Drug
Lead sponsor: Marshall University; Other
Eligibility: 18 Years to 97 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Huntington, West Virginia

Conditions: Congestive Heart Failure, Coronary Artery Disease, Myocardial Infarction
Interventions: MyoCell™ Autologous Myoblasts; Drug
Lead sponsor: Bioheart, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 5
States / cities: Fort Lauderdale, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more

Conditions: Secondary Hypogonadism
Interventions: Androxal, Placebo; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Mobile, Alabama • Little Rock, Arkansas • Garden Grove, California + 19 more

Conditions: Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Interventions: VG161, Nivolumab Injection [Opdivo]; Drug
Lead sponsor: Virogin Biotech Canada Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Sacroiliac Joint Pain
Interventions: SInergy Cooled Radiofrequency, Medical Management; Device · Other
Lead sponsor: Avanos Medical; Other
Eligibility: 21 Years to 110 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 15
States / cities: Washington D.C., District of Columbia • Bloomington, Illinois • New Orleans, Louisiana + 11 more

Conditions: Diabetic Foot
Interventions: SkinTE, Control; Biological · Other
Lead sponsor: PolarityTE; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 13
States / cities: Fresno, California • Los Angeles, California • Hollywood, Florida + 8 more

Conditions: Lymphoma
Interventions: forodesine hydrochloride; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 10
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Stanford, California + 7 more

Conditions: Irritable Bowel Syndrome
Interventions: LX1031 High Dose, LX1031 Low Dose, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 36
States / cities: Tucson, Arizona • Sherwood, Arkansas • Anaheim, California + 29 more

Conditions: Epidermolysis Bullosa (EB)
Interventions: SD-101 Dermal Cream (6%), Vehicle (SD-101 0%); Drug
Lead sponsor: Paradigm Therapeutics; Industry
Eligibility: 28 Days to 12 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Rancho Santa Margarita, California • Redwood City, California • Philadelphia, Pennsylvania + 1 more

Conditions: Systemic Lupus Erythematosus
Interventions: BMS-986165; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • El Cajon, California • Torrance, California + 21 more

Conditions: Glioblastoma Multiforme
Interventions: Lucanthone, Temozolomide (TMZ), Radiation, Placebo; Drug · Radiation
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: La Jolla, California • Orange, California • Amherst, New York + 2 more

Conditions: Foot Ulcer, Diabetes
Interventions: KC-002, Conventional Wound Therapy; Device · Other
Lead sponsor: KeraCure; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 21
States / cities: Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more

Conditions: Ulcerative Colitis
Interventions: SPD476, Asacol; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 15
States / cities: Birmingham, Alabama • Bristol, Connecticut • Washington D.C., District of Columbia + 12 more

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: Concizumab, Eptacog alfa; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa

Conditions: Cancer
Interventions: HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel; Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Scottsdale, Arizona • Boston, Massachusetts

Conditions: Agitation in Dementia, Including Alzheimer's Disease
Interventions: ITI-007, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 26
States / cities: Sun City, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 23 more

Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's
Interventions: cemsidomide, Dexamethasone Oral; Drug
Lead sponsor: C4 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more

Conditions: Schizophrenia
Interventions: iloperidone; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 59
States / cities: Birmingham, Alabama • Cerritos, California • Costa Mesa, California + 46 more

Conditions: ALK Positive Malignancies
Interventions: ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 5
States / cities: Fayetteville, Arkansas • Loma Linda, California • Aurora, Colorado + 2 more

Search by objective public record fields.

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

Single Arm Post-marketing Study of SC20 Colonoscope

Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19

Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)

Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Lateral Branch Cooled Radiofrequency Denervation vs. Conservative Therapy for Sacroiliac Joint Pain

Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers

Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Switching to Iloperidone From Other Antipsychotics in Schizophrenia

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study